AU Patent

AU2023201307A1 — Dry powder treprostinil for the treatment of pulmonary hypertension

Assigned to Liquidia Technologies Inc · Expires 2023-04-06 · 3y expired

What this patent protects

: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hy-drophobicity modifying agent,…

USPTO Abstract

: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hy-drophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hyperten-sion includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms oftreprostinil.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023201307A1
Jurisdiction
AU
Classification
—
Expires
2023-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Liquidia Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.